A · Agilent Technologies, Inc.
$115.482026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$70
-39.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($68 · $88) Analysts Range ($150 · $180) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2022.Q1 | $6.3B | — | 22.5% | 11.9% | $1.3B | −$1.2B | $83MM | 7.5% | — | 15.5% | $8.1B | $4.26 | — |
| 2023.Q1 | $6.8B | 8.4% | 24.9% | 17.1% | $1.4B | −$597MM | $821MM | 9.5% | — | 16.8% | $8.8B | $4.42 | — |
| 2024.Q1 | $6.8B | -0.2% | 20.9% | 7.2% | $1.3B | −$8MM | $1.3B | 9.4% | — | 15.3% | $8.5B | $4.37 | — |
| 2025.Q1 | $6.5B | -4.7% | 24.1% | 15.2% | $1.3B | −$998MM | $334MM | 10.6% | — | 14.9% | $9.4B | $4.54 | — |
| 2026.Q1 | $7.1B | 8.5% | 21.8% | 9.9% | $1.4B | −$515MM | $870MM | 10.2% | — | 14.3% | $9.9B | $4.54 | 21.3 |
| italics below = DCF projection · 10yr Rev CAGR: 5.2% |
| 2027.Q1 | $7.5B | +6.4% | 22.6% | 10.9% | $1.5B | −$731MM | $780MM | 9.8% | $710MM | 14.7% | $10.6B | $5.04 | 22.9 |
| 2028.Q1 | $8.0B | +6.3% | 23.4% | 11.9% | $1.6B | −$729MM | $920MM | 9.7% | $763MM | 15.0% | $11.4B | $5.50 | 21.0 |
| 2029.Q1 | $8.5B | +6.2% | 24.3% | 12.9% | $1.8B | −$723MM | $1.1B | 9.6% | $812MM | 15.3% | $12.1B | $5.99 | 19.3 |
| 2030.Q1 | $8.9B | +5.2% | 25.4% | 13.9% | $1.9B | −$647MM | $1.3B | 9.5% | $900MM | 15.7% | $12.7B | $6.50 | 17.8 |
| 2031.Q1 | $9.4B | +5.1% | 25.4% | 15.0% | $2.0B | −$670MM | $1.4B | 9.3% | $856MM | 15.5% | $13.4B | $6.75 | 17.1 |
|
| Term. Yr+ | $12.2B | 4.1% | 20.7% | 20.0% | $2.0B | −$632MM | $1.4B | 8.6% | $12.7B | 13.1% | — | — | — |
Active scenario IV: $70 (-39.7% vs market)